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SYNOPSIS 
Advanced age (>60 years) was an independent predictor of cancer-specific survival in 
patients with papillary thyroid carcinoma aged ≥ 45 years. Therefore, having another age cut-
off beyond 45 years old appears justifiable for stratifying risk of cancer-related death. This 
has important implications for current stratification systems.
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ABSTRACT 
Background: 
Although an age cut-off of 45 years has often been adopted to stratify cancer risk in papillary 
thyroid carcinoma (PTC), both cancer-specific survival (CSS) and disease-specific survival 
(DFS) continue to worsen beyond this cut-off. We aimed to see if advanced age (i.e. >60 
years) at diagnosis was an independent predictor of CSS and DFS in older (≥45 years) 
patients. 
Methods: 
Four-hundred and seven PTC patients with a minimal follow-up of 7 years were analyzed. 
Standard protocol was followed. CSS and DFS were estimated using Kaplan-Meier and 
compared with log-rank test. Variables which were significant by log-rank test were entered 
into the Cox regression analysis. 
Results: 
After a median follow-up of 15.1 years, 51 (12.5%) died of PTC while 80 (20.5%) developed 
at least one recurrence. For CSS, age >60 years (HR=3.027, 95%CI=1.369–6.690,p=0.006), 
tumor size >4cm (HR=2.043, 95%CI=1.141–4.255,p=0.049), central nodal metastases 
(HR=2.726, 95%CI=1.198–6.200,p=0.017), lateral nodal metastases (HR=5.247, 
95%CI=2.987–9.216,p<0.001) and distant metastases (HR=4.297, 95%CI=1.726–
2.506),p=0.002) were independent predictors. For DFS, only tumor size >4cm (HR=1.733, 
95%CI= 1.030 – 3.058,p=0.049), central nodal metastases (HR=2.362, 95%CI=1.010–
5.523,p=0.047) and lateral nodal metastases (HR=4.383, 95%CI=2.388–8.042,p<0.001) were 
independent predictors. 
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Conclusions: 
Advanced age was an independent predictor of CSS and there was a continuing increase in 
cancer-related death risk beyond age >60 years. However, advanced age was not an 
independent predictor of DFS. Therefore, having another age cut-off appears justifiable for 
stratifying risk of cancer-related death but less so for disease recurrence. Tumor size, central 
and lateral nodal metastases independently predicted CSS and DFS.
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INTRODUCTION 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma and its 
incidence has doubled in the past two decades [1]. Although it is generally associated with an 
excellent outcome, its prognosis depends on the presence of certain clinicopathologic 
characteristics [2]. Age at diagnosis has long been recognized as one of the most important 
prognostic factors in PTC [2,3]. Given that patients aged <45 years have significantly better 
prognosis than those aged ≥45 years, many risk stratification systems including the more 
popular 7th UICC TNM (Tumor, Node and Metastasis) staging system utilizes an age cut-off 
of 45 years to stratify risk [3]. Although this might be convenient, this strategy assumes that 
all patients aged >45 years would have a fairly uniform tumor risk regardless of whether he 
or she is significantly older or closer to the age cut-off. However, it is becoming increasingly 
clear that both the risk of cancer-related death and disease recurrence progressively increase 
even after the age of 45 years [4-9] In fact, some groups have proposed that perhaps another 
age cut-off of 60 years should be considered when stratifying tumor risk and individual 
treatment in older (≥45 years) patients [4-6]. However, to our knowledge, these studies did 
not account for other significant prognostic factors in their analysis. Furthermore, most of 
their patients had microcarcinoma and so less-than half of patients underwent total or near-
total thyroidectomy and received radioactive iodine (RAI) afterwards. Given these issues, our 
study aimed to see if advanced age at diagnosis (i.e. >60 years) remained an independent 
predictor of cancer-specific (CSS) and disease-free survivals (DFS) in older patients. This 
was carried out by analyzing a large patient cohort that had suffered clinically-significant 
PTC requiring total or near-total thyroidectomy and RAI ablation afterwards and had been 
followed up for a median of 15 years.
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PATIENTS AND METHODS 
From 1970 - 2006, 988 consecutive patients with histologically-proven PTC underwent total 
or near-total thyroidectomy in our institution. Of these, 33 (3.3%) patients with incomplete 
follow-up data were excluded while 107 (10.8%) with microcarcinoma (<1cm) and 441 
(44.6%) aged <45 years were also excluded. Therefore, 407 (41.2%) were eligible for 
analysis with a minimal follow-up of 7 years. To ensure an accurate and updated follow-up 
status of all patients, a careful manual search of all patients’ status in the territory-wide 
Clinical Management System (CMS) was performed. The CMS is a computerized database 
linking up all public hospitals and provides inpatient medical records corresponding to over 
90% of inpatient bed days in the territory. The latest date of follow-up or the date of death 
and the cause of death were recorded from the CMS. All causes of death were further 
confirmed by careful examination of the medical record, autopsy report and / or death 
certificate. All relevant clinical, pathological and perioperative data were collected 
prospectively after 1994 and follow-up data were regularly updated in a computerized 
database.  
Management of PTC 
Details of surgical treatment, RAI ablation criteria, postoperative care and follow-up protocol 
had been described previously [2] Preoperative lymphatic mapping by neck ultrasound (USG) 
was not routinely done until in the latter study period. Total or near-total thyroidectomy was 
preferred for all patients with a preoperative diagnosis of PTC. Simultaneous therapeutic 
central (level VI) +/- lateral (levels II-V) selective neck dissection was performed for 
clinically-proven cervical nodal metastasis. Prophylactic level VI neck dissection was not 
routinely performed. Two months after initial surgery, a standard ablative RAI dose of 3 
giga-Becquerels (GBq) or 80 millicuries (mCi) was given after LT4 withdrawal or with 
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recombinant TSH. TSH-suppressive LT4 treatment was commenced immediately afterwards. 
This was followed by the post-therapy scan 4-7 days later. The subsequent therapy for distant 
metastases usually comprised 5.5 GBq (or 150 mCi) RAI and was administered periodically 
every 6-month until no more uptake on scan or disease progressed despite treatment. The 
decision for RAI ablation was based on the presence of ≥1 risk factors such as tumor size > 
1.5cm, lymph node metastasis, age >45 years old, extrathyroidal extension, possible 
postoperative neck residual disease and distant metastasis. External beam radiotherapy 
(EBRT) to the neck was given to patients with extensive extrathyroidal tumor extension, 
incomplete resection, and/or extracapsular nodal metastasis. In some cases of incomplete 
resection, EBRT was given before RAI. 
Follow-up protocol 
All postoperative patients were followed up within 4 weeks in our specialized clinic. A 
follow-up visit was conducted at 3 to 6 monthly in the first 5 years and annually thereafter. 
Clinical examination and thyroglobulin (Tg) were done at each visit. Disease recurrence was 
generally made by a combination of basal Tg trend, USG, CT/ MRI or FDG-PET scan and 
confirmed by fine needle aspiration cytology (FNAC) or histology if possible while 
locoregional recurrence (LRR) was defined as an identifiable neck lesion on USG which was 
confirmed on FNAC and/or histology [10]. The exact location of LRR and distant recurrence 
were recorded. To simplify the analysis for DFS and disease recurrence, those presenting 
with distant metastases were excluded from analysis. 
Statistical analysis 
CSS and DFS were estimated using the Kaplan-Meier method and compared with log-rank 
test. Variables which were significant in the univariate analysis (by log-rank test) were 
entered into the multivariate analysis using Cox-regression analysis. All statistical analyses 
were performed using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA).
8 
 
RESULTS 
The cohort comprised mostly women (73.2%) and ethnic Chinese (92.4%). The mean age 
was 60.0 ± 10.9 years while the mean tumor size was 2.3 ± 0.9cm. There were 103 (25.3%) 
patients who presented with palpable cervical lymph node metastases while 16 (3.9%) 
presented with distant metastases. After a median follow-up of 15.1 (7.3 – 47.5) years, 51 
(12.5%) patients died of PTC while another 38 (9.3%) patients died of non-thyroidal 
malignancy and 68 (16.7%) died of a medical or natural cause. The 5-year, 10-year and 15-
year CSS were 97.0%, 93.6% and 92.0%, respectively. At the time of analysis, 18 (4.4%) 
patients were still alive with detectable local and distant disease while 11 (2.7%) patients 
were reverted to disease-free after treatment. After excluding the 16 patients who presented 
with distant metastases, there were 80 (20.5%) patients who suffered at least one recurrence 
during the study period. At the time of first recurrence, 61 (76.3%) had LRR only while 13 
(16.3%) had distant recurrence only and 6 (7.5%) had both LRR and distant recurrence. The 
5-year, 10-year and 15-year DFS were 87.2%, 80.9% and 78.8%, respectively while the 5-
year and 10-year locoregional DFS were 89.2% and 83.8%, respectively. Therefore, just over 
10% developed LRR within 5 years from initial therapy. 
Table 1 shows clinicopathological factors and treatment predictive of CSS. Age >60 years 
(p<0.001), tumor size > 4cm (p=0.003), presence of tumor multifocality (p=0.046), 
extrathyroidal extension (p<0.001), central and lateral nodal metastases (p<0.001), distant 
metastases (p<0.001), incomplete resection (p<0.001) and EBRT (p<0.001) were 
significantly associated with a worse CSS. Figure 1a shows the CSS curves between those 
aged 45 – 60 years (n=224) and those aged > 60 years (n=183). EBRT was a poor prognostic 
factor because patients who received EBRT generally had more aggressive tumor features 
and/or less complete resection (see supplementary table 1). Similar findings were found in 
patients who received RAI (see supplementary table 2). 
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Table 2 shows the multivariate analysis of risk factors for CSS. After adjusting for other 
significant factors, age >60 years (HR=3.027, 95%CI=1.369 – 6.690, p=0.006), tumor size 
>4cm (HR=2.043, 95%CI=1.141 – 4.255, p=0.049), central nodal metastases (or N1a) 
(HR=2.726, 95%CI=1.198 – 6.200, p=0.017), lateral nodal metastases (or N1b) (HR=5.247, 
95%CI=2.987 – 9.216, p<0.001) and distant metastases on presentation (HR=4.297, 
95%CI=1.726 – 2.506), p=0.002) turned out as independent predictors for CSS. These 4 
factors remained significant regardless of whether age, tumor size or both were entered as 
continuous or categorical variables. When age at diagnosis was further categorized into 45-60 
years, 61-70 years and >70 years, the overall model did not change and there was a 
progressive increase in the risk of cancer-related death with each older age category (relative 
to age of 45-60 years, HR (95%CI) for 61-70years and >70years were 2.340 (1.268 – 5.855) 
and 3.908 (1.624 – 9.205), respectively). 
Table 3 shows clinicopathological factors and treatment predictive of DFS. Age >60 years 
(p=0.015), male sex (p<0.001), study period before 1990 (p=0.027), no preoperative USG 
(p=0.006), tumor size >4cm (p<0.001), presence of extrathyroidal extension (p<0.001), 
central and lateral nodal metastases (p<0.001), incomplete resection (p=0.002), RAI (p=0.011) 
and EBRT (p=0.004) were significantly associated with a worse DFS. Figure 1b shows the 
DFS curves between those aged 45 – 60 years (n=222) and those aged >60 years (n=169). 
Those 16 patients presenting with distant metastases were excluded. Similar to CSS, RAI and 
EBRT were poor prognostic factors for DFS because patients who received either or both of 
these treatments generally had more aggressive tumor features and less complete resection. 
Table 4 the multivariate analysis of risk factors for DFS. After adjusting for other significant 
factors, only tumor size >4cm (HR=1.733, 95%CI= 1.030 – 3.058, p=0.049), central nodal 
metastases (HR=2.362, 95%CI=1.010 – 5.523, p=0.047) and lateral nodal metastases 
(HR=4.383, 95%CI=2.388 – 8.042, p<0.001) turned out as independent predictors of DFS. 
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When tumor size was entered as a continuous variable, the overall result did not change. Age 
at diagnosis did not turn out an independent predictor of DFS regardless of whether it was 
entered as a categorical or continuous variable.
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DISCUSSION 
Our data confirmed that advanced age (or age >60years) was an independent predictor of 
CSS in older patients with PTC regardless of whether it was entered as a continuous or 
categorical variable. This finding is consistent to what others have reported [4-9] and 
supports the argument that perhaps another age cut-off beyond 45 years old might be 
justifiable. Our data also showed that there was a progressive increase in risk of cancer-
related death as age increased beyond the arbitrary cut-off of 60 year old. This has important 
implications on current risk stratification systems [2]. After adjusting for other significant 
prognostic factors, the risk of cancer-related death for those aged >70 years appeared 
significantly higher than those aged between 60 – 70 years and between 45 – 60 years. In fact, 
after adjusting for other significant factors, relative to those aged 45-60 years, the risk of 
cancer-related death for those aged >60-70 years and >70 years were almost 2.5 and 4 times 
higher, respectively. Based on these findings, one may argue that perhaps, two or more cut-
offs after 45 years might be even more appropriate in further improving current risk 
stratification. Although this might be true, we believe having two separate age cut-offs after 
45 years increases the complexity of the current stratification system (namely, the TNM 
staging system) and reduces its practicality and usability [2].  
However, interestingly, unlike other recent studies [11,12], our data did not show that 
advanced age significantly increased recurrence when other significant factors had been 
adjusted for. Although there was a significantly lower 10-year DFS in those aged >60 years 
than those aged 45-60 years (74.6% vs. 84.3%, p=0.015), age>60 years did not turn out as an 
independent predictor for DFS. Therefore, from our analysis, another age cut-off might only 
be appropriate for predicting risk of cancer-related death but less so for disease recurrence in 
older patients. However, it is worth noting that given the relatively high overall LRR rate and 
a great proportion of LRR occurring shortly after initial surgery (around 10% of LRR within 
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5 years), we strongly suspect that some of these LRRs might have been persistent and 
residual diseases rather than true recurrences. One possible explanation for this is because 
preoperative USG was not routinely performed during the early study period and so some of 
these LRRs might have been non-palpable nodal metastases which later became clinically 
evident years after initial surgery.  This would also explain why no preoperative USG turned 
out a significant factor of poor DFS and why the rate of DFS significantly improved in the 
latter study period especially after year 2001 when compared to the earlier periods. Given 
these confounding factors, it was difficult to interpret the significance of advanced age on 
DFS. Nevertheless, this emphasizes the importance of having proper preoperative lymph 
node mapping by USG and perhaps, performing adequate extent of selective neck dissection 
especially in the presence of clinically nodal metastases. Perhaps, this is the precise reason 
why the dynamic or delayed risk stratification system based on response to therapy might be 
a better tool for predicting recurrences and DFS than using the traditional clinicopathologic 
features [13,14]. 
Although the overall impact of nodal metastases on cancer survival still remains under debate, 
it is clear that its impact is significantly greater in older patients. This is supported by several 
recent studies [11,12,15,16]. Similar to others, our data found that the presence of lateral 
nodal metastases (or N1b) was an independent predictor of worse CSS and DFS. In fact, 
older patients with N1b conferred over 5 times higher risk of cancer-related death than older 
patients without nodal metastases (or N0/Nx). Interestingly, the presence of central nodal 
metastases (or N1a) also conferred over 2.7 times higher risk of death than N0/Nx, although a 
significant higher risk of death was reported recently [11]. However, it is worth noting that 
since preoperative USG and prophylactic neck dissection were not routinely practiced during 
most of the study period, these results implied that perhaps only clinically-evident or palpable 
nodal metastases had any significant impact on cancer survival. 
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Similar to nodal metastases, tumor size was also found to be an independent predictor for 
CSS and DFS in older patients with PTC. This finding has also similarly reported by several 
other groups and concurs to the current 7th edition TNM staging which regards both size or 
local extent (i.e. T staging) and nodal status (N staging) as important components of stage 
groupings in patients aged ≥45 years [3]. 
Given the poorer CSS in patients aged >60 years, we would advocate a more careful and 
detailed preoperative staging assessment as well as a more aggressive surgical and 
therapeutic approach than their younger counterparts.  
Despite these findings, we acknowledged certain shortcomings. Firstly, since the number of 
patients was moderate, non-significant findings in the multivariate analysis might be due to 
inadequate power. Secondly, since this study was conducted over a long-time period, changes 
in clinical management were inevitable and might have had a confounding effect on the 
survival analyses. Also since using pre- and post-operative USG in detecting nodal 
metastases and prophylactic central neck dissection have now become routine in our practice, 
the present findings only represent our earlier experience. Therefore, larger prospective 
studies with longer follow-up period are required to confirm our findings. 
Conclusion 
Advanced age at diagnosis (>60 years) was an independent predictor of CSS in older patients 
and there was a continuing increase in risk of cancer-related death for those aged >60 years. 
However, advanced age at diagnosis was not an independent predictor of DFS or disease 
recurrence. Therefore, another age cut-off might be justifiable for stratifying risk of cancer-
related death and less so for disease recurrence in older patients with PTC. Tumor size, 
central and lateral nodal metastases independently predicted CSS and DFS in older patients.
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Table 1. Clinicopathological factors and treatments predictive of cancer-specific survival  
 Number of 
patients 
(n=407) 
Number of cancer-
related deaths 
(n=51) 
Cancer-specific survival (%) p-value* 
5-year 10-year 15-year 
Age at diagnosis   
- 45 – 60 years 
- >60 years 
 
224 (55.0) 
183 (45.0) 
 
11 (21.6) 
40 (78.4) 
 
99.1 
94.5 
 
97.5 
89.0 
 
97.5 
86.2 
<0.001 
Sex 
- Male 
- Female 
 
109 (26.8) 
298 (73.2) 
 
14 (27.5) 
37 (72.5) 
 
98.2 
96.6 
 
93.0 
93.9 
 
91.7 
92.2 
0.712 
Study period 
- ≤ 1990 
- 1991 – 2000 
- ≥ 2001 
 
110 (27.0) 
125 (30.7) 
172 (42.3) 
 
30 (58.8) 
13 (25.5) 
8 (15.7) 
 
97.2 
96.0 
97.7 
 
92.7 
93.6 
96.5 
 
91.7 
91.2 
96.5 
0.788 
Preoperative ultrasound 
- Not done 
- Done 
 
154 (37.8) 
253 (62.2) 
 
33 (64.7) 
18 (35.3) 
 
97.4 
96.8 
 
93.8 
93.6 
 
91.4 
93.6 
0.106 
Tumor size 
- ≤ 4cm 
 
346 (85.0) 
 
34 (66.7) 
 
97.9 
 
95.5 
 
93.8 
0.003 
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- > 4cm 61 (15.0) 17 (33.3) 91.5 84.4 82.6 
Tumor multifocality 
- Absent 
- Present 
 
276 (67.8) 
131 (32.2) 
 
29 (56.9) 
22 (43.1) 
 
97.0 
96.9 
 
94.5 
92.4 
 
93.2 
88.2 
0.046 
Extrathyroidal extension 
- Absent 
- Present 
 
243 (59.7) 
164 (40.3) 
 
15 (29.4) 
36 (70.6) 
 
99.6 
93.7 
 
97.5 
88.2 
 
95.8 
86.5 
<0.001 
Nodal status# 
- None (N0/Nx) 
- N1a 
- N1b 
 
247 (60.7) 
45 (11.1) 
115 (28.3) 
 
18 (35.3) 
2 (3.9) 
31 (60.8) 
 
98.7 
100.0 
91.9 
 
98.3 
97.2 
81.8 
 
96.0 
97.2 
80.6 
<0.001 
Distant metastases on presentation 
- Absent 
- Present 
 
391 (96.1) 
16 (3.9) 
 
42 (82.4) 
9 (17.6) 
 
97.1 
93.8 
 
94.6 
64.8 
 
92.9 
64.8 
<0.001 
Completeness of resection 
- Complete 
- Incomplete 
 
367 (90.2) 
40 (9.8) 
 
35 (68.6) 
16 (31.4) 
 
98.1 
87.2 
 
94.9 
81.4 
 
93.4 
78.5 
<0.001 
Radioiodine ablation      0.304 
19 
 
- Not given 
- Given 
151 (37.1) 
256 (62.9) 
19 (37.3) 
32 (62.7) 
96.7 
97.3 
94.4 
93.2 
94.4 
90.5 
External radiation therapy 
- Not given 
- Given 
 
351 (86.2) 
56 (13.8) 
 
34 (66.7) 
17 (33.3) 
 
97.7 
92.7 
 
95.7 
81.5 
 
94.5 
77.5 
<0.001 
Categorical variables are expressed as number (percentage) 
*using Log-rank test 
#by 7th edition TNM staging system
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Table 2. A multivariate analysis of clinicopathological risk factors for cancer-specific survival 
Covariates ß-coefficient Hazard ratio (95% confidence 
interval) 
p-value 
 Age at diagnosis^ 
- 45 – 60 years 
- >60 years 
 
 
1.107 
 
1 
3.027 (1.369 – 6.690) 
0.006 
Tumor size+ 
- ≤ 4cm 
- > 4cm 
 
 
0.281 
 
1 
2.043 (1.141 – 4.255) 
0.049 
Tumor multifocality 
- Absent 
- Present 
 
 
0.294 
 
1 
1.342 (0.718 – 2.506) 
0.357 
Extrathyroidal extension 
- Absent 
- Present 
 
 
0.335 
 
1 
1.398 (0.647 – 3.022) 
0.394 
Nodal status# 
- None (N0/Nx) 
- N1a 
- N1b 
 
 
1.003 
1.658 
 
1 
2.726 (1.198 – 6.200) 
5.247 (2.987 – 9.216) 
 
 
0.017 
<0.001 
DM on presentation 
- Absent 
- Present 
 
 
1.458 
 
1 
4.297 (1.726 – 2.506) 
0.002 
Completeness of resection 
- Complete 
- Incomplete 
 
 
0.227 
 
1 
1.255 (0.586 – 2.689) 
0.389 
External radiation therapy   0.172 
21 
 
- Not given 
- Given 
 
0.531 
1 
1.701 (0.794 – 3.641) 
DM = distant metastases 
#based on 7th edition TNM staging system 
+when tumor size was entered as a continuous variable, HR (95%CI) became 1.184 (1.035 – 
1.354), p=0.014 
^when age was entered as a continuous variable, HR (95%CI) became 1.061 (1.027 – 1.095), 
p<0.001
22 
 
Table 3. Clinicopathological factors and treatment predictive of disease-free survival^ 
 Number of 
patients 
(n=391) 
Number of 
persistent/recurrent 
diseases (n=80) 
Disease-free survival (%) p-value* 
5-year 10-year 15-year 
Age at diagnosis 
- 45 – 60 years 
- >60 years 
 
222 (56.8) 
169 (43.2) 
 
37 (46.3) 
43 (53.8) 
 
88.8 
83.6 
 
84.3 
74.6 
 
81.5 
73.4 
0.015 
Sex 
- Male 
- Female 
 
104 (26.6) 
287 (73.4) 
 
33 (41.3) 
47 (58.8) 
 
78.9 
89.3 
 
68.8 
83.9 
 
65.6 
82.3 
<0.001 
Study period 
- ≤ 1990 
- 1991 – 2000 
- ≥ 2001 
 
104 (26.6) 
123 (31.5) 
164 (41.9) 
 
30 (37.5) 
30 (37.5) 
20 (25.0) 
 
82.7 
85.6 
89.5 
 
74.5 
76.8 
86.4 
 
71.8 
75.2 
86.4 
0.027 
Preoperative ultrasound 
- Not done 
- Done 
 
148 (37.9) 
243 (62.1) 
 
42 (52.5) 
38 (47.5) 
 
81.1 
90.0 
 
74.7 
84.8 
 
72.0 
84.8 
0.006 
Tumor size 
- ≤ 4cm 
 
332 (84.9) 
 
57 (71.3) 
 
88.9 
 
84.1 
 
82.0 
<0.001 
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- > 4cm 59 (15.1) 23 (28.8) 74.6 62.6 60.2 
Tumor multifocality 
- Absent 
- Present 
 
268 (68.5) 
123 (31.5) 
 
51 (63.8) 
29 (36.3) 
 
88.5 
82.0 
 
82.3 
76.3 
 
79.3 
76.3 
0.299 
Extrathyroidal extension 
- Absent 
- Present 
 
240 (61.4) 
151 (38.6) 
 
32 (40.0) 
48 (60.0) 
 
91.5 
80.0 
 
87.7 
70.4 
 
85.6 
68.4 
<0.001 
Nodal status 
- None (N0/Nx) 
- N1a 
- N1b 
 
243 (62.1) 
44 (11.3) 
104 (26.6) 
 
21 (26.3) 
12 (15.0) 
47 (58.8) 
 
95.8 
79.5 
70.3 
 
93.1 
74.4 
56.3 
 
91.0 
74.4 
53.1 
<0.001 
Completeness of resection 
- Complete 
- Incomplete 
 
358 (91.6) 
33 (8.4) 
 
67 (83.8) 
13 (16.3) 
 
89.0 
66.7 
 
83.0 
60.5 
 
80.5 
60.5 
0.002 
Radioiodine ablation 
- None 
- Given 
 
151 (38.6) 
240 (61.4) 
 
21 (26.3) 
59 (73.8) 
 
91.0 
85.0 
 
88.2 
76.5 
 
86.1 
74.5 
0.011 
External radiation therapy      0.004 
24 
 
- None 
- Given 
337 (86.2) 
54 (13.8) 
61 (76.3) 
19 (23.8) 
88.7 
77.8 
83.2 
66.5 
81.1 
64.4 
Categorical variables are expressed as number (percentage) 
*using Log-rank test 
^ patients presenting with distant metastases were excluded from analysis
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Table 4. A multivariate analysis of clinicopathological risk factors for disease-free survival 
Covariates ß-coefficient Hazard ratio (95% confidence 
interval) 
p-value 
 Age at diagnosis^ 
- 45 – 60 years 
- >60 years 
 
 
0.066 
 
1 
1.068 (0.643 – 1.773) 
0.800 
Sex 
- Male 
- Female 
 
 
0.386 
 
1 
0.680 (0.409 – 1.131) 
0.137 
Study period 
- ≤ 1990 
- 1991 – 2000 
- ≥ 2001 
 
 
0.189 
0.514 
 
1 
0.827 (0.461 – 1.486) 
0.598 (0.301 – 1.190) 
0.143 
Preoperative ultrasound 
- Not done 
- Done 
 
 
0.419 
 
1 
0.664 (0.387 – 1.140) 
0.664 
Tumor size+ 
- ≤4cm 
- >4cm 
 
 
0.550 
 
1 
1.733 (1.030 – 3.058) 
0.049 
Extrathyroidal extension 
- Absent 
- Present 
 
 
0.292 
 
1 
1.339 (0.760 – 2.360) 
0.313 
Nodal status# 
- None (N0/Nx) 
- N1a 
- N1b 
 
 
0.859 
1.478 
 
1 
2.362 (1.010 – 5.523) 
4.383 (2.388 – 8.042) 
 
 
0.047 
<0.001 
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Completeness of resection 
- Complete 
- Incomplete 
 
 
0.281 
 
1 
1.325 (0.698 – 2.514) 
0.389 
Radioiodine ablation 
- None 
- Given 
 
 
0.256 
 
1 
1.292 (0.725 – 2.301) 
0.385 
External radiation therapy 
- None 
- Given 
 
 
0.054 
 
1 
1.056 (0.554 – 2.014) 
0.869 
#based on 7th edition TNM staging system 
+when tumor size was entered as a continuous variable, HR (95%CI) became 1.203 (1.077 – 
1.343), p =0.001.  
^when age was entered as a continuous variable, HR (95%CI) became 1.005 (0.983 – 1.027), 
p=0.763.
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LEGENDS 
 
Figure 1a. Cumulative disease-specific survival curves of papillary thyroid carcinoma between 
those aged 45 – 60 years (n=224) and those aged > 60 years (n=183). 
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Figure 1b. Cumulative disease-free survival curves of papillary thyroid carcinoma between those 
aged 45 – 60 years (n=222) and those aged > 60 years (n=169). Those 16 patients presenting 
with distant metastases were excluded. 
